Twitxy
Saved
@buur_stougaard's profile picture
View on X

Elisabeth Buur Stougaard

@buur_stougaard

Joined May 2022
14 Following 26 Followers 15 Posts

Latest posts 5

Elisabeth Buur Stougaard @buur_stougaard
The #Steno1 trial is now initiated! Aiming to include 2000 persons with type 1 diabetes at high risk of CVD and CKD and with the potential to change the way we treat complications to type 1 diabetes.
#SDCC, #SDCA
#SDCN, #SDCS
#SDCO, #SDCG, #SDCF
Steno Diabetes Center Copenhagen @Stenodiabetes Jul 11, 2024
Forskere fra hele kongeriget vil revolutionere behandlingen af #type1diabetes 👏 🌟 Det sker med studiet Steno 1, som netop er påbegyndt. Læs mere: sdcc.dk/presse-og-nyhe… #steno1
Video preview
View quoted post on X
Elisabeth Buur Stougaard @buur_stougaard
Just published:
#SDCC
Time Trends in the Incidence of Diabetic Ketoacidosis Leading to Hospital Admission Among Adults With Type 1 Diabetes—A Nationwide Danish Register Study diabetesjournals.org/care/article-a…
diabetesjournals.org Time Trends in the Incidence of Diabetic Ketoacidosis Leading to Hospital Admission Among Adults... OBJECTIVE. Diabetic ketoacidosis (DKA) is a life-threatening but preventable complication in people with type 1 diabetes. We aimed to quantify the incidenc
Elisabeth Buur Stougaard @buur_stougaard
Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, reduces the risk of cardiovascular and kidney disease, as assessed by the Steno T1 Risk Engine in adults with type 1 diabetes
@FrederikPersson, @DorteVistisen,
@P_Rossing
dom-pubs.onlinelibrary.wiley.com/doi/10.1111/do…
dom-pubs.onlinelibrary.wiley.com Sotagliflozin, a dual sodium‐glucose co‐transporter‐1 and sodium‐glucose co‐transporter‐2 inhibit... Aims Sotagliflozin (SOTA) as adjunct to insulin therapy improves glycemic control, reduces body weight and blood pressure, and increases time in range in adults with type 1 diabetes (T1D). SOTA...